The "Egg Timer Challenge": Faster Re-Forecasting in Life Sciences Webinar
November 7, 2017 | 1:00PM
Rapid changes in the biopharmaceutical industry require manufacturers to analyze and respond quickly to market events. Biosimilars, a crowded innovator market, new indications, policy changes, and shifting treatment paradigms require continual re-assessment of forecasts, and the need for many “what-if” analyses. Meanwhile, existing forecasting techniques require hours or days to analyze, reducing your ability to make decisions and act quickly.
In this webinar, we’ll first introduce a new metric to measure your critical forecasting tasks: “Forecasting Cycle Time”. This metric measures the time-to-alter a forecast, from start to presentation of analytical findings. Using this metric, you can understand how quickly your organization can react to change, and where improvements may be needed. Next, you will learn how forecasts can be constructed to allow re-forecasting to be done efficiently – in three minutes or less. Finally, we’ll introduce you to the “Egg Timer Challenge”: a challenge for forecasting teams to build forecasts that reduce cycle time (including regional analysis) to no more than three minutes.
Rick Johnston, Ph.D.
Senior Enterprise Software Lead
Rick serves as Enterprise Software Expert for the practice. His focus is on building analytically complex business decisions at the asset and portfolio level. Enterprise software tools he has developed are actively used by 22 of the top 25 pharma companies. Rick holds a Ph.D. in Industrial Engineering and Bioinformatics from UC Berkeley.
David leads the US Strategy and Portfolio Analysis team at IQVIA. He has assisted clients with a wide range of issues including product valuations, analog analyses, user-friendly valuation models, etc. Before joining IQVIA, David worked as a Senior Consultant for Arthur Andersen and Co. within the litigation consulting group. David holds an MBA from Stanford University.
Sam specializes in leading client projects with biotechnology and pharmaceutical companies focused on portfolio management and asset-level strategy development. He has extensive experience collaborating with functional teams in R&D, forecasting, market research, pricing and marketing. He also co-leads our client delivered model team. Sam holds an MBA from Stanford University